Rectal budesonide: A potential game changer after Kasai hepatoportoenterostomy
Journal of Pediatric Gastroenterology and Nutrition · 2025
DOI: 10.1002/jpn3.70147 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, 2025. Verfasst von Stefanie Langreen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric and Adolescent Surgery, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: Budesonide, Portoenterostomy, Hepatic, Glucocorticoids, Biliary Atresia. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: None.
Abstract (Originalsprache)
Objectives
Intravenous or oral steroid administration in patients with biliary atresia (BA) after Kasai hepatoportoenterostomy (HPE) is commonly practiced, however, the benefits remain controversial. Some studies suggest no positive effects while risking steroid associated side effects. Rectal application of glucocorticoids has so far only been assessed by our group with promising short‐term results. We now aim to evaluate the impact of rectal budesonide administration on long‐term native liver survival in patients undergoing HPE for BA.
Methods
We performed a retrospective cohort study and included all patients after HPE who received rectal budesonide (2 mg) for 3 months from 2011 to 2022, compared to a historical control group without any glucocorticoid treatment. Jaundice‐free native liver survival (jfNLS) was assessed at 6 months, 2 years, 5 years, and 10 years post‐Kasai. Serious adverse effects of budesonide were documented.
Results
Our analysis confirmed our previously published improvements in jfNLS at 6 months (53% vs. 39%) and 2 years (45% vs. 22%), while revealing sustained benefits at 5 years (40% vs. 23%) and 10 years (32% vs. 13%). However, these benefits were exclusive to patients with nonsyndromic BA. No serious budesonide‐associated adverse side effects were found.
Conclusions
Our findings support the efficacy of rectal budesonide application in enhancing long‐term outcomes, providing a safe therapeutic approach and improving jfNLS after HPE for BA, without severe adverse effects. Prospective randomized controlled trials are required to further evaluate its potential post‐Kasai benefits and compare it to systemic glucocorticoid therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric and Adolescent Surgery, Hannover Medical School, Hannover, Germany.
- Department of Kidney, Liver and Metabolic Disease, Division of Pediatric Gastroenterology and Hepatology, Hannover Medical School, Hannover, Germany.
- Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
ORCID-Profile: Stefanie Langreen
Förderung
- None
Zitieren
APA
Langreen, S., Pauer, N., Pfister, E. D., Junge, N., Baumann, U., Madadi-Sanjani, O., Petersen, C., Dingemann, J., & Schukfeh, N. (2025). Rectal budesonide: A potential game changer after Kasai hepatoportoenterostomy. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.70147
Vancouver
Langreen S, Pauer N, Pfister ED, Junge N, Baumann U, Madadi-Sanjani O, et al. Rectal budesonide: A potential game changer after Kasai hepatoportoenterostomy. Journal of Pediatric Gastroenterology and Nutrition. 2025. doi:10.1002/jpn3.70147
BibTeX
@article{Langreen2025,
author = {Langreen, Stefanie and Pauer, Nathalie and Pfister, Eva D and Junge, Norman and Baumann, Ulrich and Madadi-Sanjani, Omid and Petersen, Claus and Dingemann, Jens and Schukfeh, Nagoud},
title = {Rectal budesonide: A potential game changer after Kasai hepatoportoenterostomy},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2025},
doi = {10.1002/jpn3.70147}
}
EUVIMED